AstraZeneca acquires EsoBiotec in $1 bn deal

AstraZeneca acquires EsoBiotec in $1 bn deal

18 Mar 2025

British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of biotechnology company EsoBiotech in a $1 billion transaction

AstraZeneca starts global recall of its controversial Covid 19 vaccine

AstraZeneca starts global recall of its controversial Covid 19 vaccine

08 May 2024

Days after admitting that its Covid 19 vaccine could cause blood clot in some people, British-Swedish pharmaceutical company AstraZeneca

AstraZeneca to buy China's Gracell Biotechnologies for $1.2 bn

AstraZeneca to buy China's Gracell Biotechnologies for $1.2 bn

27 Dec 2023

Anglo-Swedish multinational pharmaceutical and biotechnology company AstraZeneca has agreed to acquire China-based Gracell Biotechnologies Inc, for about $1.2 billion.

AstraZeneca to acquire CinCor Pharma in a deal worth $1,8 bn

11 Jan 2023

AstraZeneca to acquire biotech firm TeneoTwo in a deal worth more than $1.27 billion

08 Jul 2022

AstraZeneca to acquire Alexion in a $39 bn cash-and-stock deal

23 Dec 2020

India may grant emergency use authorisation for Oxford-AstraZeneca Covid-19 vaccine: report

24 Nov 2020

AstraZeneca Covid-19 vaccine trial volunteer in Brazil dies; testing to continue

26 Oct 2020

Sun Pharma licenses AstraZeneca to sell its oncology drugs in China

06 Nov 2019

AstraZeneca and Merck claim Japanese approval for anti-cancer drug Lynparza

20 Jun 2019

Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.

Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!

Start your free subscription today!

Latest articles on AstraZeneca from Informachine

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

17 Aug 2026

Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer

17 Aug 2026

Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on Tagrisso

17 Aug 2026

Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy

31 Jul 2026

Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant

27 Jul 2026

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

27 Jul 2026

H1 and Q2 2026 results

27 Jul 2026

Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer

24 Jul 2026

Trixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthma

24 Jul 2026

Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer

23 Jul 2026

View details about the software product Informachine News Trackers